This article is more than 5 years old. Information may no longer be current.

Bausch + Lomb begins Technolas Teneo clinical trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch + Lomb has initiated the first clinical trial for its Technolas Teneo excimer laser for myopia and myopic astigmatism correction surgery, the company announced in a press release.

The multicenter, prospective, open-label, nonrandomized study will evaluate the safety and efficacy of the Technolas Teneo 317 (model 2) excimer laser in LASIK surgery.

“This is an exciting milestone for our organization, as it’s the first step on the road to filing for regulatory approval for the Teneo laser in the United States,” Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb, said in the release. “Teneo has been well received and widely adopted in more than 50 markets globally as one of the most versatile lasers on the market with the added benefit of a compact footprint, and we look forward to bringing this technology to surgeons and their patients in the United States, as well.”